We have previously reported that pretreatment with high-dose Yiqifumai (80 mg kg-1), compared to low (15 mg kg-1) and medium (30 mg kg-1) dose group, significantly attenuates LPS-induced microcirculatory disturbance in rat mesentery, including reduction in the number of adherent leukocytes, the intensity of DHR fluorescence, degradation of mast cell, albumin leakage, and the expression of CD11b/CD18, suggesting that Yiqifumai is a promising regime for treatment of LPS-evoked sepsis thanks to its multiple targeting potential for the initial steps of the process [7]. Here, ALB is linked to Sepsis.